- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Doug Drysdale
Recent news which mentions Doug Drysdale
Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
June 03, 2025
Tickers
CYBN
From Benzinga
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
November 15, 2023
Tickers
CYBN
From Benzinga
Cybin Stock Down On Laying Off 15% Of Workforce As Part Of A Streamlining Clinical Alignment
February 23, 2023
Tickers
CYBN
From Benzinga
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
February 01, 2023
From Benzinga
From Benzinga
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
August 30, 2022
Tickers
CYBN
From Benzinga
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
August 17, 2022
From Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 2022
Tickers
CYBN
From Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
June 10, 2022
From Benzinga
From Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
May 31, 2022
Tickers
CYBN
From Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
April 22, 2022
Tickers
CYBN
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
February 09, 2022
Tickers
CYBN
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Tickers
CYBN
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
November 08, 2021
Tickers
CYBN
From Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.